NCT02512042View on ClinicalTrials.gov

Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

PHASE3CompletedINTERVENTIONAL
Enrollment

973

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

May 31, 2016

Conditions
Glaucoma
Interventions
DRUG

Test-Brinzolamide 1% Ophthalmic suspension

DRUG

Reference-Brinzolamide 1% Ophthalmic suspension

Trial Locations (10)

30076

Coastal Research Associates, LLC, Roswell

30260

Eye Care Centers Management, Inc., Morrow

33144

AMB Research Center, Inc., Miami

33773

Shettle Eye Research, Inc., Largo

63131

Ophthalmology Associates, St Louis

66204

Heart of America Eye Care PA, Shawnee Mission

78240

Keystone Research Ltd., San Antonio

78731

Keystone Research Ltd., Austin

89074

Las Vegas Physicians Research Group, Henderson

92663

David Wirta, MD, Newport Beach

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT02512042 - Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes | Biotech Hunter | Biotech Hunter